UMN Pharma Inc. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,140,486.00
4,002,394.00
3,390,038.00
14,390,757.00
158,422.00
726,674
Depreciation, Depletion & Amortization
1,404,400.00
1,873,257.00
1,524,361.00
1,237,256.00
-
-
Other Funds
197.00
6,251.00
-
25,200.00
5,040.00
128,835
Funds from Operations
3,684,210.00
318,926.00
2,308,456.00
2,356,401.00
484,999.00
597,841
Changes in Working Capital
105,750.00
4,261.00
1,085,340.00
91,197.00
76,724.00
19,358
Net Operating Cash Flow
3,578,460.00
314,665.00
3,393,796.00
2,265,204.00
561,723.00
578,483
Capital Expenditures
4,319,810.00
8,310.00
409,664.00
1,844,137.00
-
Sale of Fixed Assets & Businesses
7,500.00
-
-
-
-
Purchase/Sale of Investments
168,057.00
409.00
11,239.00
2,000.00
50.00
Net Investing Cash Flow
4,150,619.00
8,719.00
398,425.00
1,842,137.00
50.00
Issuance/Reduction of Debt, Net
4,020,716.00
5,928,790.00
2,535,574.00
1,174,946.00
1,426,771.00
Net Financing Cash Flow
8,113,793.00
2,493,382.00
2,554,122.00
4,243,372.00
1,729,946.00
Net Change in Cash
384,714.00
2,187,436.00
1,238,099.00
136,031.00
1,168,173.00
Free Cash Flow
7,472,599.00
309,661.00
3,800,860.00
4,108,882.00
561,723.00
Other Sources
11,985.00
-
-
-
-
Change in Capital Stock
4,093,274.00
3,441,659.00
18,548.00
3,043,226.00
308,215.00
Other Uses
18,351.00
-
-
-
-

About UMN Pharma

View Profile
Address
4-2-3 Gosyonoyumoto
Akita Akita 010
Japan
Employees -
Website http://www.umnpharma.com
Updated 07/08/2019
UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It develops vaccines targeting influenza, norovirus, and rotavirus. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan.